6-K - Satellos Bioscience Inc. Common Stock | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Satellos Bioscience Inc. reported its 2025 financial results, including a net loss of $24.9 million, and highlighted clinical progress for SAT-3247 with the initiation of the BASECAMP Phase 2 pediatric trial and continued data from the TRAILHEAD adult study. The company completed a $57.2 million equity financing in February 2026, extending its cash runway through 2027.

Key Takeaways

1Reported net loss of $24.9 million ($1.70 loss per basic and diluted common share) for the year ended Dec. 31, 2025.

2Completed a US$57.2 million equity financing on Feb. 9, 2026, with common shares beginning to trade on Nasdaq under ticker 'MSLE' on Feb. 6, 2026.

3Initiated BASECAMP, a global, randomized, placebo-controlled Phase 2 clinical trial of SAT-3247 in pediatric DMD patients, with first participant dosed on Feb. 12, 2026.

4Presented interim data from TRAILHEAD Phase 2 adult study showing maintained or improved handgrip strength over 9 to 13 months in four participants.

5Appointed Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs on Jan. 29, 2026, and Mark Nawacki to the Board of Directors on Nov. 14, 2025.

6Cash and cash equivalents and short-term investments were $27.7 million as of Dec. 31, 2025, with cash runway expected to extend through 2027.

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Results of Operations

Full Year 2025

Metric	Value	Prior Period
Net Loss	$24.90	$20.60
Loss Per Basic and Diluted Common Share	$1.70	$2.16
Research and Development Expenses	$18.40	$14.40
General and Administrative Expenses	$8.00	$6.00

Executive & Director Changes

Antoinette Paone

Chief Development Officer and Head of Regulatory Affairs

Appointed

Effective: 2026-01-29

Mark Nawacki

Board of Directors

Appointed

Effective: 2025-11-14

Exhibits (2)

6-K

FORM 6-K

99.1

PRESS RELEASE